Jeremy Bender Sells 15,894 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 15,894 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the transaction, the chief executive officer owned 177,165 shares in the company, valued at approximately $1,578,540.15. This trade represents a 8.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $8.41 on Thursday. The stock has a 50 day moving average price of $7.68 and a 200 day moving average price of $7.06. Day One Biopharmaceuticals, Inc. has a one year low of $5.64 and a one year high of $14.46. The stock has a market capitalization of $863.51 million, a price-to-earnings ratio of -5.53 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million for the quarter, compared to analysts’ expectations of $38.20 million. The firm’s quarterly revenue was down 57.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.38 EPS. On average, analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors have recently made changes to their positions in DAWN. Federated Hermes Inc. purchased a new position in Day One Biopharmaceuticals in the third quarter worth approximately $39,000. Quarry LP purchased a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $49,000. Ameritas Investment Partners Inc. lifted its stake in Day One Biopharmaceuticals by 44.5% during the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares in the last quarter. Quantbot Technologies LP acquired a new position in Day One Biopharmaceuticals during the 1st quarter worth about $82,000. Finally, Entropy Technologies LP purchased a new position in shares of Day One Biopharmaceuticals in the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of recent research reports. HC Wainwright cut their price objective on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Piper Sandler lifted their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Needham & Company LLC dropped their target price on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $24.43.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.